What Is Low Dose Methotrexate and How Does It Work?

Low-dose methotrexate is a once-weekly medication, typically taken at 5 to 25 mg per week, that suppresses overactive immune responses rather than killing cancer cells. Originally developed as a high-dose chemotherapy agent for childhood leukemia, methotrexate was repurposed decades later at a fraction of that dose to treat autoimmune and inflammatory diseases. The way it calms inflammation turns out to be surprisingly different from how it fights cancer, and understanding that distinction helps explain both why the drug works so well and why it comes with a specific set of side effects and precautions.

From Cancer Drug to Immune Modulator

Methotrexate was discovered as a treatment for childhood leukemia before becoming the standard of care for rheumatoid arthritis and several other inflammatory conditions. The key difference between its two lives lies in dose. High-dose methotrexate, used in oncology, can reach hundreds of milligrams per square meter of body surface. Low-dose methotrexate, by contrast, sits in a range roughly a hundredth of that. At those smaller weekly doses, the drug does not obliterate fast-dividing cells the way chemotherapy does. Instead, it recalibrates immune signaling through a set of pathways that researchers spent years untangling.

How Low-Dose Methotrexate Actually Works

The textbook explanation starts with an enzyme called dihydrofolate reductase, or DHFR. Methotrexate blocks this enzyme, which cells need to produce the building blocks of DNA. In high-dose cancer therapy, that blockade is the whole point: rapidly dividing tumor cells cannot copy their DNA and die. At low doses, some of this still happens to activated immune cells, slowing down the lymphocytes that drive autoimmune inflammation.

But researchers now believe the more important mechanism at low doses involves adenosine. When methotrexate partially blocks folate-dependent pathways, a byproduct called adenosine accumulates outside cells. Adenosine acts as a natural brake on inflammation. Studies in mice have shown that low-dose weekly methotrexate increases adenosine concentrations in inflamed tissue, and that the anti-inflammatory effect depends on a specific adenosine receptor called A2A. Mice engineered to lack that receptor did not benefit from methotrexate, while mice lacking a different adenosine receptor (A3) responded normally.

There is also a cellular retention mechanism that extends methotrexate’s effects between weekly doses. Inside cells, the drug gets converted into longer molecules called polyglutamates. These polyglutamate forms are harder for cells to pump out, so they linger and continue to inhibit folate-dependent enzymes long after the original drug would have been cleared. The longer the polyglutamate chain, the more tightly it binds and the longer it stays.

³ This polyglutamate formation is a big part of why the drug can be taken just once a week rather than every day.⁴

What Conditions It Treats

Rheumatoid arthritis is the flagship indication. Low-dose methotrexate at 10 to 25 mg per week, used alone or combined with other drugs, is the cornerstone of RA treatment and has been for over 25 years. Placebo-controlled trials have established it as first-line therapy, and its long track record means doctors generally start with methotrexate before moving to newer, more expensive biologics.

⁵⁶

Psoriasis is another major use. In a long-term observational study, patients with moderate-to-severe plaque psoriasis saw their disease severity scores drop by about half after six months on methotrexate, and those improvements held steady through four years of follow-up.

⁷

Crohn’s disease is a less commonly discussed use, but methotrexate has evidence behind it here too. A Cochrane review found that intramuscular methotrexate kept roughly two-thirds of Crohn’s patients in remission at 40 weeks, compared to about 40 percent on placebo. The number needed to treat to prevent one relapse was four, which is a fairly strong result.

⁸ There is also emerging data in pediatric Crohn’s disease, where methotrexate as a first-line maintenance therapy showed clinical remission in about 60 percent of children by week 14, with high rates of mucosal healing by one year.⁹

The drug also has a role in rarer conditions. In a form of blood vessel inflammation called ANCA-associated vasculitis, a randomized trial demonstrated that methotrexate could replace the much more toxic drug cyclophosphamide for inducing remission in patients with early, non-kidney-threatening disease.

¹⁰

Oral Versus Subcutaneous and Why the Route Matters

Methotrexate comes in both pill and injectable forms, and the two are not interchangeable in terms of how much drug your body actually absorbs. Oral methotrexate has a cap on absorption. Above about 15 mg, the gut cannot transport much more of the drug, so doubling the pill dose does not double the amount that reaches your bloodstream. Subcutaneous injection bypasses this ceiling entirely, delivering a dose-proportional increase at every step up. Studies measuring total drug exposure found that the subcutaneous route delivered roughly 35 percent more drug at a 7.5 mg dose and as much as 68 percent more at 30 mg compared to the same oral dose.

¹¹

Subcutaneous injection also leads to higher accumulation of those polyglutamate forms inside red blood cells during the early treatment phase, which may translate to faster onset of effect.

¹² And a meta-analysis found that the subcutaneous route cut gastrointestinal side effects, particularly diarrhea, by roughly 40 to 60 percent compared to oral dosing.¹³ In practice, many patients start with pills and switch to injections if they cannot tolerate the nausea or if the oral dose seems insufficient.

Common Side Effects

The most frequent complaint is gastrointestinal trouble. In one hospital-based study, about 31 percent of patients on low-dose methotrexate reported some form of GI disturbance, including nausea, vomiting, or abdominal pain. Liver enzyme elevations showed up in about 14 percent, and mouth sores and hair thinning occurred in roughly 10 percent each.

¹⁴ Life-threatening events like severe drops in blood cell counts or drug-induced lung inflammation are rare and can often be anticipated if clinicians watch for warning signs and risk factors.¹⁵

Fatigue is another common but underappreciated side effect. Many patients describe a “methotrexate hangover” the day after their dose, with tiredness, brain fog, and mild malaise that clears within a day or two. This is not a formal clinical endpoint that gets measured in most trials, so it tends to be underrepresented in the published literature, but it is one of the leading reasons patients ask to change therapy.

Why Folic Acid Goes With Methotrexate

Since methotrexate works partly by interfering with folate metabolism, supplementing with folic acid can offset some of the collateral damage without undermining the drug’s anti-inflammatory effect. A Cochrane review found that folic acid or its close cousin folinic acid reduced GI side effects by about a quarter, slashed the risk of liver enzyme spikes by roughly 77 percent, and cut the rate of patients discontinuing methotrexate for any reason by about 60 percent. The same review found no evidence that folate supplementation made the RA less well controlled.

¹⁶

A separate systematic review confirmed the protective effect on liver enzymes and GI symptoms, though it could not definitively settle whether folate dulled methotrexate’s efficacy because the disease-activity measures used across trials were inconsistent.

¹⁷ In practice, nearly all rheumatology guidelines now recommend taking folic acid at least once a week (and often daily) alongside methotrexate. If your prescriber did not mention it, ask.

Drug-Induced Lung Inflammation

The most feared rare complication is hypersensitivity pneumonitis, a form of drug-induced lung inflammation. It most often shows up within the first year of starting methotrexate, though case reports document it appearing after 15 or even 30 years of continuous use.

¹⁸ Symptoms typically include a dry cough and shortness of breath. Risk factors include being over 60, having diabetes or pre-existing lung disease, kidney problems, and low blood albumin levels. Most patients recover fully after stopping methotrexate and receiving corticosteroids, but mortality rates in published case series can run as high as about 18 percent, which is why any new respiratory symptoms on methotrexate deserve prompt medical attention.

¹⁹

Drug Interactions That Matter

Methotrexate is cleared primarily through the kidneys. Anything that reduces kidney function or competes for the same elimination pathways can push methotrexate levels dangerously high. Common anti-inflammatory painkillers (NSAIDs) and high-dose aspirin slow the kidney’s excretion of methotrexate and raise its blood concentration, which is worth knowing because many RA and psoriasis patients take these drugs regularly. Corticosteroids, by contrast, have been found to be safe alongside methotrexate.

²⁰

The most dangerous pairing is with the antibiotic trimethoprim-sulfamethoxazole, commonly prescribed for urinary tract and other infections. Both drugs hit the folate pathway, and together they can cause a catastrophic drop in blood cell counts. This interaction is well-documented enough to carry its own case-report literature. If you are on methotrexate and need an antibiotic, make sure every prescriber involved knows about it.

²⁰

Pregnancy, Fertility, and Timing

Methotrexate is a known teratogen, meaning it can cause birth defects. Both women and men are typically advised to stop methotrexate well before trying to conceive. Guidelines have traditionally recommended waiting at least three months after the last dose, and some providers advise six months to be safe. A recent retrospective cohort study looked at whether conception timing relative to the last methotrexate dose affected birth defect rates. The adjusted odds of congenital malformations were similar whether conception happened one to three months, three to six months, or more than six months after the last dose, suggesting the three-month washout may be sufficient in most cases.

²¹ Still, this was observational data, and no one is running a randomized trial on this question for obvious ethical reasons. The standard advice remains to plan ahead and discuss washout timing with your rheumatologist and obstetrician.

Pairing Methotrexate With Biologic Drugs

Methotrexate is frequently kept on board even after a patient starts a biologic medication like adalimumab (Humira) or similar drugs. The reason is not just additive anti-inflammatory effect. Methotrexate reduces the body’s tendency to form antibodies against biologic drugs, which can neutralize them and cause them to stop working over time. In a multicenter randomized trial of patients with spinal inflammatory arthritis on adalimumab, those who also took methotrexate had significantly higher adalimumab blood levels and roughly half the rate of anti-drug antibody formation compared to those on adalimumab alone. The co-treatment group was also more likely to still be on adalimumab at long-term follow-up.

²²

This “immunogenicity shield” is one of the most underappreciated roles of methotrexate. Even at low doses (sometimes as low as 10 mg per week), it can meaningfully extend the useful life of expensive biologic therapies. For patients who tolerate methotrexate well, keeping it in the regimen alongside a biologic is often a pragmatic choice that protects the investment in the more costly drug.

Routine Monitoring and Blood Work

Regular lab tests are a non-negotiable part of methotrexate therapy. Before starting, most guidelines call for baseline blood counts, liver enzymes, kidney function tests, and often a chest X-ray. Japanese claims data covering over half a million patients showed that baseline blood work was performed in virtually all cases, while chest imaging was done in about 70 percent. After treatment starts, monitoring of kidney function increased significantly.

²³

How frequently blood work is repeated varies by specialty. Rheumatology and dermatology guidelines do not always agree, particularly on how many liver enzymes to check and how often. One study found that stricter dermatology monitoring protocols actually led to patients stopping methotrexate sooner than rheumatology protocols did, raising the question of whether over-monitoring can itself be counterproductive by catching clinically insignificant lab blips that trigger unnecessary discontinuation.

²⁴

Why Genetics Might Explain Variable Responses

Not everyone responds to methotrexate the same way, and researchers have been looking at whether genetic differences in folate-processing enzymes or drug-transport proteins could explain why some patients get great results and others get mostly side effects. Variants in genes like MTHFR and SLC19A1 have been studied, but the picture is messy. Several studies have linked certain variants to a higher rate of adverse effects, while fewer have found consistent links to how well the drug actually works. For now, pharmacogenomic testing for methotrexate is not part of routine clinical practice, though it remains an active area of research.

²⁵

The Failed Experiment in Heart Disease Prevention

Because chronic inflammation plays a role in atherosclerosis, and because methotrexate is good at tamping down inflammation, a large randomized trial called CIRT tested whether low-dose methotrexate could prevent heart attacks and strokes in patients with stable coronary artery disease. The trial enrolled thousands of patients and compared weekly methotrexate to placebo. The result was unambiguously negative. Methotrexate did not lower levels of key inflammatory markers like interleukin-6 or C-reactive protein, and cardiovascular events occurred at virtually identical rates in both groups.

²⁶

The CIRT result was a useful scientific lesson. Around the same time, a different trial (CANTOS) showed that a drug targeting a more specific inflammatory pathway, interleukin-1β, did reduce cardiovascular events. The takeaway was that not all anti-inflammatory strategies are interchangeable. Methotrexate’s mechanism, centered on adenosine and folate pathways, does not appear to reach the particular inflammatory circuits that drive plaque rupture in arteries. The drug remains excellent at what it does, but heart disease prevention is not in its repertoire.